Maiwald Magazine

Press Coverage

25 Aug 2025 - Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

9 Jul 2025 - Press Coverage

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

Maiwald in the press

Publications

2 Sep 2025 - Publication

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

In its ruling on EP 3 536 712 B1, the Düsseldorf Local Division of the UPC for the first time outlined crucial criteria for patent infringement based on second medical use cl...

18 Jul 2025 - Publication

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

In a specialist article, Kerstin Wolff analyzes the current state of EU regulation on new genomic techniques (NGTs). In February 2024, the European Parliament proposed exempti...

11 Jun 2025 - Publication

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...

All publications

Events

Mon.

13 Oct 2025 |Upcoming

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

We are pleased to announce that Maiwald Intellectual Property will participate as a Platinum Partner at the upcoming Life Sciences Strategy Summit on IP & Exclusivity, taking place in the Infinity Hotel & Conference Resort Munich from 13–15 October 2025.

Tue.

21 Oct 2025 |Upcoming|External Events

Maiwald at IAM Live: Auto IP Europe 2025

IAM Live: Auto IP Europe 2025 is a significant trade event that unites experts from the automotive and IP sectors. The focus is on the latest challenges, trends and developments in intellectual property for the automotive industry. Participants can look forward to in-depth presentations and practical discussions on topics such as patents, design rights, technology transfer...

Wed.

5 Nov 2025 |Upcoming|Seminar

Maiwald Mandanten-Seminar in Düsseldorf on November 5, 2025: Update IP-Strategies

As the year draws to a close, we cordially invite you to our Maiwald Mandanten-Seminar in Düsseldorf. The presentations will provide information on current developments in the field of intellectual property law and offer an opportunity for mutual exchange. Agenda

Tue.

18 Nov 2025 |Upcoming|External Events

Maiwald is Gold Partner for the 2nd „Pharma and Biotech Patent Litigation North America“ conference

On 18 and 19 November, the second annual Pharma & Biotech Patent Litigation North America conference will take place at the Marriott Downtown in Philadelphia. Maiwald is proud to support this important event as a Gold Partner. Dr Eva Ehlich will participate in a panel discussion. The topic is how life science compani...

All events

News and Releases

Maiwald Blog

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

Staff News

Marvin Bäumel sworn in as German patent attorney

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Dr. Patrick Heeger and Dr. Andre Mähringer sworn in as German patent attorneys

Publications

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

Awards

Managing IP’s Rising Stars 2025

FOCUS List of Top Commercial Law Firms in Germany 2025

Handelsblatt: The best law firms in Germany 2025

Events

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

Maiwald at IAM Live: Auto IP Europe 2025

Maiwald Mandanten-Seminar in Düsseldorf on November 5, 2025: Update IP-Strategies

Maiwald is Gold Partner for the 2nd „Pharma and Biotech Patent Litigation North America“ conference